Copy the short URL in each article and paste it new tab
Wednesday, May 6, 2015
Breakingviews: Alexion's pricey play
The rare-disease drugmaker's $8.4 billion bid for rival Synageva includes a 136 percent premium, but Robert Cyran and Reynolds Holding explain why that could make sense.
from Reuters Video: Breakingviews http://ift.tt/1c6emsM
via IFTTT
No comments:
Post a Comment